Zacks Research Has Bullish Estimate for PAHC FY2026 Earnings

Key Points

• Zacks Research raised its FY2026 EPS estimate for Phibro Animal Health to $2.99 and assigned the stock a Strong-Buy, while also forecasting $3.07 for FY2027 and $3.18 for FY2028.
• Phibro beat its latest quarter expectations with $0.87 EPS (vs. $0.69 expected) and $373.9M revenue (vs. $355.6M expected), and the company set FY2026 guidance at $2.93–$3.10 EPS.
• Insiders have been net sellers (CEO sold 7,040 shares and insiders sold 316,472 shares in the last quarter), as the stock trades with a $2.38B market cap, a P/E of 26.07, and a 0.8% dividend yield.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Zacks Research upped their FY2026 earnings per share (EPS) estimates for shares of Phibro Animal Health in a research report issued to clients and investors on Wednesday, April 8th. Zacks Research analyst Team now anticipates that the company will post earnings of $2.99 per share for the year, up from their previous forecast of $2.98. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health's Q4 2026 earnings at $0.67 EPS, Q1 2027 earnings at $0.78 EPS, Q2 2027 earnings at $0.79 EPS, Q4 2027 earnings at $0.79 EPS, FY2027 earnings at $3.07 EPS and FY2028 earnings at $3.18 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS.

PAHC has been the topic of several other reports. Weiss Ratings reissued a "buy (b-)" rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $37.50.

Phibro Animal Health Stock Performance

NASDAQ PAHC opened at $58.66 on Thursday. The firm has a market capitalization of $2.38 billion, a P/E ratio of 26.07, a P/E/G ratio of 0.85 and a beta of 0.69. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $59.68. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The business's 50-day simple moving average is $51.49 and its 200-day simple moving average is $44.21.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. 1620 Investment Advisors Inc. increased its holdings in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock worth $25,000 after purchasing an additional 295 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock worth $27,000 after purchasing an additional 386 shares during the last quarter. Rothschild Investment LLC increased its holdings in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock worth $39,000 after purchasing an additional 1,000 shares during the last quarter. Hughes Financial Services LLC purchased a new stake in Phibro Animal Health during the 3rd quarter worth approximately $40,000. Finally, iSAM Funds UK Ltd purchased a new stake in Phibro Animal Health during the 3rd quarter worth approximately $61,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $52.52, for a total transaction of $369,740.80. Following the sale, the chief executive officer directly owned 73,320 shares in the company, valued at $3,850,766.40. The trade was a 8.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 316,472 shares of company stock worth $15,265,419. 50.13% of the stock is owned by insiders.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were given a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 0.8%. Phibro Animal Health's payout ratio is 21.33%.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.